BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clin Genitourin Cancer 2019;17:e447-53. [PMID: 30799129 DOI: 10.1016/j.clgc.2019.01.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu XH, Zou QM, Cao JD, Wang ZC. Primary squamous cell carcinoma with sarcomatoid differentiation of the kidney associated with ureteral stone obstruction: A case report . World J Clin Cases 2022; 10(32): 11942-11948 [DOI: 10.12998/wjcc.v10.i32.11942] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Shan L, Shao X, Gu L, Wu M, Lin P, Yu Z, Chen Q, Zhu D. Clinicopathologic factors linked to oncologic outcomes for renal cell carcinoma with sarcomatoid dedifferentiation: A PRISMA-compliant systematic review and meta-analysis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.922150] [Reference Citation Analysis]
3 Hahn AW, Lebenthal J, Genovese G, Sircar K, Tannir NM, Msaouel P. The significance of sarcomatoid and rhabdoid dedifferentiation in renal cell carcinoma. Cancer Treat Res Commun 2022;33:100640. [PMID: 36174377 DOI: 10.1016/j.ctarc.2022.100640] [Reference Citation Analysis]
4 Zuo Y, Fu S, Zhao Z, Li Z, Wu Y, Qi T, Zheng J, Du Q, Xu Z, Yu N. Sarcomatoid-associated gene risk index for clear cell renal cell carcinoma. Front Genet 2022;13:985641. [DOI: 10.3389/fgene.2022.985641] [Reference Citation Analysis]
5 xing Z, Chen Y, Cai G, Chen S. Clinical characteristic and survival analysis of distant metastatic sarcomatoid renal cell carcinoma: A study of 378 patients.. [DOI: 10.21203/rs.3.rs-1567322/v2] [Reference Citation Analysis]
6 Studentova H, Rusarova N, Ondruskova A, Zemankova A, Student V, Skanderova D, Melichar B. The Role of Cytoreductive Nephrectomy in Renal Cell Carcinoma with Sarcomatoid Histology: A Case Series and Review of the Literature. Current Oncology 2022;29:5475-5488. [DOI: 10.3390/curroncol29080433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Patel HD, Man A, Koehne EL, Rac G, Aragao AP, Flanigan RC, Gorbonos A, Gupta GN, Woods ME, Picken MM, Quek ML. Percentage of sarcomatoid histology is associated with survival in renal cell carcinoma: Stratification and implications by clinical metastatic stage. Urologic Oncology: Seminars and Original Investigations 2022;40:347.e1-347.e8. [DOI: 10.1016/j.urolonc.2022.04.003] [Reference Citation Analysis]
8 Whaley RD, Cheng L. Clinicopathologic and Immunohistochemical Characterization of Sarcomatoid Chromophobe Renal Cell Carcinoma: An Analysis of 22 Cases. Am J Surg Pathol 2022. [PMID: 35687360 DOI: 10.1097/PAS.0000000000001926] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Warli SM, Andy A, Mariedina CT, Nasution R, Kadar DD. A Rare Case of Sarcomatoid Renal Cell Carcinoma in a Young Adult Patient. RRU 2022;Volume 14:241-245. [DOI: 10.2147/rru.s370975] [Reference Citation Analysis]
10 Lu Z, He W, Zhou J, Yang C, Xiang R. Construction and validation of a novel prognostic nomogram for patients with metastatic renal cell carcinoma: a SEER-based study. J Int Med Res 2022;50:3000605221105367. [PMID: 35726570 DOI: 10.1177/03000605221105367] [Reference Citation Analysis]
11 Al-juhaishi T, Deng X, Bandyopadhyay D, Paul A. The Role of Cytoreductive Nephrectomy and Targeted Therapy on Outcomes of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Population-Based Analysis. Cureus 2022. [DOI: 10.7759/cureus.25395] [Reference Citation Analysis]
12 Fuu T, Iijima K, Kusama Y, Otsuki T, Kato H. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report. J Med Case Rep 2022;16:193. [PMID: 35581611 DOI: 10.1186/s13256-022-03426-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Janisch F, Kienapfel C, Fühner C, Klotzbücher T, Marks P, Hillemacher T, Meyer CP, Iwata T, Parizi MK, Sauter G, Fisch M, Shariat SF, Dahlem R, Rink M. Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. Front Surg 2021;8:763271. [PMID: 34869564 DOI: 10.3389/fsurg.2021.763271] [Reference Citation Analysis]
14 Sejima T, Masago T, Yoshida M, Nishi T, Kawabata Y, Tajima Y, Yumioka T, Honda M, Takenaka A. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy. Int Cancer Conf J 2021;10:285-9. [PMID: 34567939 DOI: 10.1007/s13691-021-00501-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun 2021;12:808. [PMID: 33547292 DOI: 10.1038/s41467-021-21068-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
16 Zoumpourlis P, Genovese G, Tannir NM, Msaouel P. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds. Clin Genitourin Cancer 2021;19:103-16. [PMID: 33358151 DOI: 10.1016/j.clgc.2020.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
17 Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
18 Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Alaiwi SA, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant’angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-ivins M, Hirsch L, Wind-rotolo M, Ross-macdonald P, Sun M, Lee GM, Chang SL, Wei XX, Mcgregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, Mcdermott DF, Heng DY, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative Molecular Characterization of Sarcomatoid and Rhabdoid Renal Cell Carcinoma Reveals Determinants of Poor Prognosis and Response to Immune Checkpoint Inhibitors.. [DOI: 10.1101/2020.05.28.121806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Hou G, Li X, Zheng Y, Liu P, Yan F, Ju D, Zhang G, Zheng W, Gao M, Hou N, Yuan J, Wang F, Yuan J. Construction and validation of a novel prognostic nomogram for patients with sarcomatoid renal cell carcinoma: a SEER-based study. Int J Clin Oncol 2020;25:1356-63. [PMID: 32361824 DOI: 10.1007/s10147-020-01681-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Zhao Y, Chen H, Xie Y, Zhang C, Hou Y, Jin M. Clinicopathologic features and prognostic factors in patients with renal cell carcinoma with sarcomatoid differentiation. APMIS 2020;128:378-86. [PMID: 32048364 DOI: 10.1111/apm.13035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
21 Buonerba C, Dolce P, Iaccarino S, Scafuri L, Verde A, Costabile F, Pagliuca M, Morra R, Riccio V, Ribera D, De Placido P, Romeo V, Crocetto F, Longo N, Imbimbo C, De Placido S, Di Lorenzo G. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Cancers (Basel) 2020;12:E408. [PMID: 32050629 DOI: 10.3390/cancers12020408] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
22 Debien V, Thouvenin J, Lindner V, Barthélémy P, Lang H, Flippot R, Malouf GG. Sarcomatoid Dedifferentiation in Renal Cell Carcinoma: From Novel Molecular Insights to New Clinical Opportunities. Cancers (Basel) 2019;12:E99. [PMID: 31906050 DOI: 10.3390/cancers12010099] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
23 Marszalek M. First-line treatment of metastatic renal cell carcinoma: current standard of care. memo 2019;12:334-338. [DOI: 10.1007/s12254-019-00550-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]